Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
von
, 15.02.2020, 18:00 Uhr
Bristol-Myers Squibb Company (NYSE: BMY) today announced updated results from the Phase 3 CheckMate -214 study evaluating the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). With a minimum follow-up of 42 months, the combination of Opdivo plus Yervoy continues to show superior overall